Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
In patients treated with Nexavar, hypertension was generally mild to moderate, occurred early in the course of treatment, and was managed with standard antihypertensive therapy. Monitor blood pressure weekly during the first 6 weeks of therapy with Nexavar and periodically thereafter, treating as required.